Literature DB >> 11701469

In vivo complex formation of oxidized alpha(1)-antitrypsin and LDL.

S Mashiba1, Y Wada, M Takeya, A Sugiyama, T Hamakubo, A Nakamura, N Noguchi, E Niki, A Izumi, M Kobayashi, K Uchida, T Kodama.   

Abstract

An inactivated form of alpha(1)-antitrypsin (AT) and LDL coelutes in gel permeation chromatography. To characterize and to quantify the amount of this fraction of AT, a monoclonal antibody was established against chloramine T-oxidized AT and named OxAT-4. OxAT-4 recognized the oxidatively modified AT, including hexylaldehyde- or 4-hydroxy-2-nonenal-modified AT, but neither normal active AT nor trypsin/AT complex. Comigration of apoB and oxidized AT was demonstrated by Western blotting analysis of AT-LDL by means of anti-apoB monoclonal antibody and OxAT-4. A complex of oxidized AT and LDL (AT-LDL) was isolated from human plasma LDL by affinity column with an OxAT-4 antibody-coated carrier. AT-LDL was degraded 4 times more effectively by mouse peritoneal macrophages, but this was not mediated by scavenger receptor class A type I. Localization of AT-LDL was detected in human atherosclerotic lesions of the coronary artery, but distribution of it was not completely identical to that of macrophages. In situ hybridization revealed AT expression by macrophages, which were present in intimal layers of the coronary artery. From these findings, we concluded that AT is produced and oxidized by macrophages, then attached to LDL in the intimal layer of the arterial wall. Although AT-LDL that escapes into the blood stream can be cleared by hepatocytes, the remaining AT-LDL may be taken up by macrophages and contribute to the lipid accumulation in arterial wall cells as the early stage of atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11701469     DOI: 10.1161/hq1101.098232

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  22 in total

1.  Common coding variant in SERPINA1 increases the risk for large artery stroke.

Authors:  Rainer Malik; Therese Dau; Maria Gonik; Anirudh Sivakumar; Daniel J Deredge; Evgeniia V Edeleva; Jessica Götzfried; Sander W van der Laan; Gerard Pasterkamp; Nathalie Beaufort; Susana Seixas; Steve Bevan; Lisa F Lincz; Elizabeth G Holliday; Annette I Burgess; Kristiina Rannikmäe; Jens Minnerup; Jennifer Kriebel; Melanie Waldenberger; Martina Müller-Nurasyid; Peter Lichtner; Danish Saleheen; Peter M Rothwell; Christopher Levi; John Attia; Cathie L M Sudlow; Dieter Braun; Hugh S Markus; Patrick L Wintrode; Klaus Berger; Dieter E Jenne; Martin Dichgans
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-06       Impact factor: 11.205

2.  Rosuvastatin Alters the Proteome of High Density Lipoproteins: Generation of alpha-1-antitrypsin Enriched Particles with Anti-inflammatory Properties.

Authors:  Scott M Gordon; Benjamin McKenzie; Georgina Kemeh; Maureen Sampson; Shira Perl; Neal S Young; Michael B Fessler; Alan T Remaley
Journal:  Mol Cell Proteomics       Date:  2015-10-19       Impact factor: 5.911

Review 3.  Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies.

Authors:  Stanley M H Chan; Stavros Selemidis; Steven Bozinovski; Ross Vlahos
Journal:  Pharmacol Ther       Date:  2019-02-26       Impact factor: 12.310

Review 4.  Expanding the clinical indications for α(1)-antitrypsin therapy.

Authors:  Eli C Lewis
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

5.  Scavenger receptor class B, type I-mediated uptake of A1AT by pulmonary endothelial cells.

Authors:  Angelia D Lockett; Daniela N Petrusca; Matthew J Justice; Christophe Poirier; Karina A Serban; Natalia I Rush; Malgorzata Kamocka; Dan Predescu; Sanda Predescu; Irina Petrache
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-06-19       Impact factor: 5.464

Review 6.  Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats.

Authors:  O Guttman; B M Baranovski; R Schuster; Z Kaner; G S Freixo-Lima; N Bahar; N Kalay; M I Mizrahi; I Brami; D E Ochayon; E C Lewis
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

7.  Alpha-1 Antitrypsin Therapy for Autoimmune Disorders.

Authors:  Sihong Song
Journal:  Chronic Obstr Pulm Dis       Date:  2018-10-05

8.  α-Linoleic acid enhances the capacity of α-1 antitrypsin to inhibit lipopolysaccharide induced IL-1β in human blood neutrophils.

Authors:  Nupur Aggarwal; Elena Korenbaum; Ravi Mahadeva; Stephan Immenschuh; Veronika Grau; Charles A Dinarello; Tobias Welte; Sabina Janciauskiene
Journal:  Mol Med       Date:  2016-10-04       Impact factor: 6.354

9.  Neutrophil/lymphocyte ratio is correlated with levels of inflammatory markers and is significantly reduced by smoking cessation.

Authors:  Maki Komiyama; Yuka Ozaki; Yusuke Miyazaki; Yasufumi Katanasaka; Yoichi Sunagawa; Masafumi Funamoto; Kana Shimizu; Hajime Yamakage; Noriko Sato-Asahara; Akihiro Yasoda; Hiromichi Wada; Tatsuya Morimoto; Koji Hasegawa
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.671

10.  The effect of vitamin E-bonded polysulfone membrane dialyzer on a new oxidative lipid marker.

Authors:  Yuki Kitamura; Kumi Kamimura; Noriko Yoshioka; Yoko Hosotani; Kenji Tsuchida; Masahide Koremoto; Jun Minakuchi
Journal:  J Artif Organs       Date:  2013-02-10       Impact factor: 1.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.